Business
OncBioMune Receives Notice of Allowance for Patent Covering New Targeted Cancer Treatments
OncBioMune Receives Notice of Allowance for Patent Covering New Targeted Cancer Treatments.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Receives Notice of Allowance for Patent Covering New Targeted Cancer Treatments \n\nOncBioMune Receives Notice of Allowance for Patent Covering New Targeted Cancer Treatments\n\n\nUSPTO Issues New Patent for Cancer Vaccine Technology \n\n\n BATON ROUGE, LA--(Marketwired - January 22, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application #13/017,173 that covers the Company's transferrin transport technology for developing new, targeted cancer treatments. The patent to be issued from this allowed application, titled \"Taxane-and taxoid-protein compositions,\" carries a patent term to at least 2031.This is the first patent that seeks to protect OncBioMune's novel transferrin transport technology. Specifically, claims in the patent cover novel compositions comprising the protein transferrin, and a taxane or taxoid, which does not utilize a linking group between the taxane and protein. The claims cover drug development utilizing the technology for a broad spectrum of cancers, including, but not limited to sarcoma, lymphoma, leukemia, prostate, lung and breast. OncBioMune's transferrin transport technology is an innovative approach to chemotherapy that we believe represents an improvement of current cancer treatments that have already been proven effective, but come with limitations due to toxicity towards healthy cells and inefficient delivery specific to the tumor, amongst other things. Similarly the drug Abraxane®, which is estimated to have generated nearly $1 billion in sales in 2015, utilizes paclitaxel bound to human albumin to treat cancer to increase the effectiveness of the paclitaxel. \"This patent is a very important addition to our intellectual property portfolio, as we believe our targeted therapeutics under its umbrella can represent the next generation of taxane and taxoid-based cancer treatments,\" commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. \"Although their ability to slow cell proliferation is well known, taxanes are particularly insoluble, ...